Dexcom announced it has acquired TypeZero. Recall, TypeZero has developed a proprietary inControl algorithm for insulin dose adjustments. The acquisition is viewed as highly positive for both sides: Dexcom gains future revenue streams and IP while TypeZero investors are able to exit with a presumably attractive return. Below, FENIX provides insight into the acquisition.
Medtronic hosted its CY Q2 ’18 (FY Q1 ’19) earnings (press release) and provided a brief update to its diabetes business unit. Below are highlights from the call.
Medtronic announced the launch of its “Inner Circle” patient engagement program for patients on either the 670G hybrid closed-loop or the standalone Guardian Connect CGM. Recall, Medtronic initially disclosed its plans for Inner Circle during the June 2018 Investor Day.
ADA has issued an updated position statement on the treatment of pediatric patients with T1DM.
Senseonics hosted its Q2 ’18 earnings call and provided insight into their raised financial guidance, the recent Eversense implantable CGM US launch, and LCM activities. Below, FENIX provides highlights from the call, in addition to insight on a potential Senseonics acquisition strategy targeted at Roche Diabetes Care.
Express Scripts has released its Exclusion List Changes for the 2019 National Preferred commercial formulary.
Senseonics has announced the official US launch of the Eversense CGM as well as its first commercial coverage by Horizon BCBS of New Jersey and Horizon Healthcare of New Jersey. According to the press release, product shipments began the last week of July. Tomorrow, August 8, 2018, Senseonics is holding its Q2 ’18 earnings call and will likely provide more insight into the Eversense launch.
Dexcom hosted its Q2 ’18 earnings call and provided updates to its CGM marketing and pipeline activities. Of note, Terry Gregg, former CEO and Chairman of the Board, has retired. Kevin Sayer, Dexcom’s current CEO, will fill the position. Below are highlights from the call.
FDA has approved an extended, 14-day wear time (previously 10-day) for Abbott Freestyle Libre in addition to reducing sensor warm-up time to 1 hour (previously 12 hours). In response to this expanded approval, Dexcom’s stock price dropped ~6% today. Abbott has not issued a press release yet, and the Libre US website is not yet updated. Below, FENIX provides insight into the Libre label update as it relates to the CGM market.
Roche hosted its Q2 ’18 earnings call and briefly discussed its diabetes devices portfolio including Solo micropump, which recently received CE Mark. Importantly, Roche senior management disclosed their intentions to bring the Solo micropump to the US. Below are highlights from the call including insights from Roche’s recent collaboration and investment in Care Innovations.